Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum.

Ohsuga T, Yamaguchi K, Kido A, Murakami R, Abiko K, Hamanishi J, Kondoh E, Baba T, Konishi I, Matsumura N.

BMC Cancer. 2017 Aug 29;17(1):580. doi: 10.1186/s12885-017-3573-1.

2.

Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy.

La V, Fujikawa R, Janzen DM, Nunez M, Bainvoll L, Hwang L, Faull K, Lawson G, Memarzadeh S.

NPJ Precis Oncol. 2017;1. pii: 7. doi: 10.1038/s41698-017-0008-z. Epub 2017 Apr 3.

3.

Hyper-phosphorylation of Sequestosome-1 Distinguishes Resistance to Cisplatin in Patient Derived High Grade Serous Ovarian Cancer Cells.

Nguyen EV, Huhtinen K, Goo YA, Kaipio K, Andersson N, Rantanen V, Hynninen J, Lahesmaa R, Carpen O, Goodlett DR.

Mol Cell Proteomics. 2017 Jul;16(7):1377-1392. doi: 10.1074/mcp.M116.058321. Epub 2017 Apr 28.

PMID:
28455291
4.

Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients.

Liu R, Zeng Y, Zhou CF, Wang Y, Li X, Liu ZQ, Chen XP, Zhang W, Zhou HH.

Sci Rep. 2017 Feb 2;7(1):18. doi: 10.1038/s41598-017-00050-w.

5.

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer.

Coveney C, Boocock DJ, Rees RC, Deen S, Ball GR.

Microarrays (Basel). 2015 Jul 17;4(3):324-38. doi: 10.3390/microarrays4030324.

6.

Downregulation of vimentin expression increased drug resistance in ovarian cancer cells.

Huo Y, Zheng Z, Chen Y, Wang Q, Zhang Z, Deng H.

Oncotarget. 2016 Jul 19;7(29):45876-45888. doi: 10.18632/oncotarget.9970.

7.

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.

Mignogna C, Staropoli N, Botta C, De Marco C, Rizzuto A, Morelli M, Di Cello A, Franco R, Camastra C, Presta I, Malara N, Salvino A, Tassone P, Tagliaferri P, Barni T, Donato G, Di Vito A.

J Ovarian Res. 2016 May 21;9(1):31. doi: 10.1186/s13048-016-0238-7.

8.

MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.

Pénzváltó Z, Lánczky A, Lénárt J, Meggyesházi N, Krenács T, Szoboszlai N, Denkert C, Pete I, Győrffy B.

BMC Cancer. 2014 Nov 18;14:837. doi: 10.1186/1471-2407-14-837.

9.

Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics.

Engelberth SA, Hempel N, Bergkvist M.

Crit Rev Oncog. 2014;19(3-4):281-315. Review.

10.
11.

Phosphoproteomic analysis of gossypol-induced apoptosis in ovarian cancer cell line, HOC1a.

Jin L, Chen Y, Mu X, Lian Q, Deng H, Ge R.

Biomed Res Int. 2014;2014:123482. doi: 10.1155/2014/123482. Epub 2014 Aug 12.

12.

Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.

Jin L, Huo Y, Zheng Z, Jiang X, Deng H, Chen Y, Lian Q, Ge R, Deng H.

Mol Cell Proteomics. 2014 Nov;13(11):3138-51. doi: 10.1074/mcp.M113.033217. Epub 2014 Aug 5.

13.

FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer.

Zhou J, Wang Y, Wang Y, Yin X, He Y, Chen L, Wang W, Liu T, Di W.

PLoS One. 2014 May 13;9(5):e96989. doi: 10.1371/journal.pone.0096989. eCollection 2014.

14.

Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.

Sama AR, Schilder RJ.

Int J Womens Health. 2014 Jan 28;6:149-57. doi: 10.2147/IJWH.S40889. eCollection 2014. Review.

15.

Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer.

Zhang P, Zhang P, Shi B, Zhou M, Jiang H, Zhang H, Pan X, Gao H, Sun H, Li Z.

Cell Death Dis. 2014 Jan 9;5:e991. doi: 10.1038/cddis.2013.526.

16.

Empirical chemosensitivity testing in a spheroid model of ovarian cancer using a microfluidics-based multiplex platform.

Das T, Meunier L, Barbe L, Provencher D, Guenat O, Gervais T, Mes-Masson AM.

Biomicrofluidics. 2013 Jan 10;7(1):11805. doi: 10.1063/1.4774309. eCollection 2013.

17.

(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.

Lheureux S, Lecerf C, Briand M, Louis MH, Dutoit S, Jebahi A, Giffard F, Fournier CB, Batalla A, Poulain L, Aide N.

Transl Oncol. 2013 Oct 1;6(5):586-95. eCollection 2013.

18.

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.

Leamon CP, Lovejoy CD, Nguyen B.

Pharmgenomics Pers Med. 2013 Sep 25;6:113-25. doi: 10.2147/PGPM.S24943. Review.

19.

Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.

Hagemann AR, Novetsky AP, Zighelboim I, Gao F, Massad LS, Thaker PH, Powell MA, Mutch DG, Wright JD.

Gynecol Oncol. 2013 Dec;131(3):535-40. doi: 10.1016/j.ygyno.2013.09.032. Epub 2013 Oct 4.

20.

Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.

Kang HJ, Chun SM, Kim KR, Sohn I, Sung CO.

PLoS One. 2013 Aug 13;8(8):e72609. doi: 10.1371/journal.pone.0072609. eCollection 2013.

Supplemental Content

Support Center